Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion.

Emerging data suggest that SBRT may be comparable with surgery for definitive treatment of stage I NSCLC in certain patients. When is one approach preferred and in whom?

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...